Shares of Glenmark Pharmaceuticals Ltd were trading in the green and 1% higher on 23 October after the company announced that its US affiliate, Glenmark Pharmaceuticals Inc., will offer Ropivacaine Hydrochloride Injection USP in the US market.

The medicine will be offered in single-dose vials containing 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL).

Glenmark Pharmaceuticals stated that the injection is bioequivalent and therapeutically equivalent to Naropin injection, which is made by Fresenius Kabi USA LLC.Ropivacaine injections are used to numb specific areas of the body prior to or during surgery or childbirth.

It can also be used to treat acute or severe pain. The injection is used as an anesthetic to numb specific parts of the body prior to or during surgery or childbirth, as well as to alleviate acute discomfort.Glenmark Pharmaceuticals Inc. intends to begin marketing of the medicine in November 2025.

According to IQVIA sales statistics for the 12-month period ending August 2025, the Naropin Injection market generated an annual revenue of roughly $20.9 million.

“This launch represents another important addition to Glenmark’s expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need,” Marc Kikuchi, President and Business Head, North America, said.

Glenmark’s Ropivacaine Hydrochloride Injection is only approved for the indications specified on the approved label.

At 12:40 pm, Glenmark Pharma’s shares were trading at ₹1,856.90, up 0.08% on the NSE.